Scynexis (SCYX) Profit After Tax Growth (3y) (2016 - 2026)
Powered by 
Analysis
Scynexis (SCYX) Profit After Tax Growth (3y) (2016 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 19.87% |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -129.22% |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 6.30% |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 10.23% |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 91.31% |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 17.25% |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 37.44% |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | -45.23% |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - | -60.74% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -60.74% |
| Mar 31, 2026 | 14.33% |
| Dec 31, 2025 | 41.77% |
| Sep 30, 2025 | 33.78% |
| Jun 30, 2025 | 19.80% |
| Mar 31, 2025 | 0.37% |
| Dec 31, 2024 | 46.70% |
| Sep 30, 2024 | -66.81% |
| Jun 30, 2024 | -120.50% |
| Mar 31, 2024 | 27.81% |
| Dec 31, 2023 | 22.89% |
| Sep 30, 2023 | -57.85% |
| Jun 30, 2023 | 176.59% |
| Mar 31, 2023 | -69.13% |
| Dec 31, 2022 | 0.07% |
| Sep 30, 2022 | -55.02% |
| Jun 30, 2022 | -16.67% |
| Mar 31, 2022 | 38.03% |
| Dec 31, 2021 | -157.51% |
| Sep 30, 2021 | -55.00% |